CHMP recommends Ryzodeg combination (Novo Nordisk) for treatment of Diabetes
On 18 October 2012, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ryzodeg, 100 units/mL, solution for injection from Novo Bordisk, intended for the treatment of diabetes mellitus. The active substances of Ryzodeg are insulin degludec and insulin aspart, a soluble insulin product consisting of the basal insulin degludec and the rapid-acting prandial insulin aspart. Insulin degludec and insulin aspart bind specifically to the human insulin receptor and results in the same pharmacological effects as human insulin.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins